Laparoscopic Roux-en-Y gastric bypass versus laparoscopic mini gastric bypass in the treatment of obesity: study protocol for a randomized controlled trial

被引:8
作者
Kraljevic, Marko [1 ]
Delko, Tarik [1 ]
Kostler, Thomas [2 ]
Osto, Elena [3 ]
Lutz, Thomas [4 ]
Thommen, Sarah [5 ]
Droeser, Raoul A. [1 ]
Rothwell, Lincoln [6 ]
Oertli, Daniel [1 ]
Zingg, Urs [2 ]
机构
[1] Univ Hosp Basel, Dept Gen Surg, CH-4031 Basel, Switzerland
[2] Limmattal Hosp, Dept Gen Surg, CH-8952 Zurich, Switzerland
[3] ETH, IFNH Lab Translat Nutr Biol, CH-8603 Schwerzenbach, Switzerland
[4] Univ Zurich, Inst Vet Physiol, Vetsuisse Fac, CH-8057 Zurich, Switzerland
[5] Univ Hosp Basel, Basel Inst Clin Epidemiol & Biostat, CH-4031 Basel, Switzerland
[6] Ipswich Gen Hosp, Dept Gen Surg, Ipswich, Qld 4305, Australia
来源
TRIALS | 2017年 / 18卷
关键词
Randomized controlled trial; Roux-en-Y gastric bypass; Mini gastric bypass; Outcome; Excess weight loss; BARIATRIC SURGERY; MORTALITY;
D O I
10.1186/s13063-017-1957-9
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Laparoscopic Roux-en-Y gastric bypass (LRYGB) is considered the gold standard in bariatric surgery, achieving durable long-term weight loss with improvement of obesity-related comorbidities. Lately, the laparoscopic mini gastric bypass (LMGB) has gained worldwide popularity with similar results to LRYGB in terms of weight loss and comorbidity resolution. However, there is a lack of randomized controlled trials (RCT) comparing LMGB and LRYGB. This article describes the design and protocol of a randomized controlled trial comparing the outcomes of these two bariatric procedures. Methods/Design: The trial is designed as a single center, randomized, patient and observer blinded trial. The relevant ethics committee has approved the trial protocol. To demonstrate that LMGB is not inferior to LRYGB in terms of excess weight loss (EWL) the study is conducted as a non-inferiority trial with the sample-size calculations performed accordingly. EWL 12 months after surgery is the primary endpoint, whereas 3-year EWL, morbidity, mortality, remission of obesity related comorbidities, quality of life (QOL) and hormonal and lipid profile changes are secondary endpoints. Eighty patients, 18 years or older and with a body mass index (BMI) between 35 and 50 kg/m(2) who meet the Swiss guidelines for the surgical treatment of morbid obesity will be randomized. The endpoints and baseline measurements will be assessed pre-surgery, peri-surgery and post-surgery (fixed follow up measurements are at discharge and at the time points 6 weeks and 12 and 36 months postoperatively). Discussion: With its 3-year follow up time, this RCT will provide important data on the impact of LMGB and LRYGB on EWL, remission of comorbidities, QOL and hormonal and lipid profile changes.
引用
收藏
页数:9
相关论文
共 24 条
  • [1] HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, TOTAL CHOLESTEROL SCREENING, AND MYOCARDIAL-INFARCTION - THE FRAMINGHAM-STUDY
    ABBOTT, RD
    WILSON, PWF
    KANNEL, WB
    CASTELLI, WP
    [J]. ARTERIOSCLEROSIS, 1988, 8 (03): : 207 - 211
  • [2] Long-term mortality after gastric bypass surgery
    Adams, Ted D.
    Gress, Richard E.
    Smith, Sherman C.
    Halverson, R. Chad
    Simper, Steven C.
    Rosamond, Wayne D.
    LaMonte, Michael J.
    Stroup, Antoinette M.
    Hunt, Steven C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (08) : 753 - 761
  • [3] Exploring the impact of bariatric surgery on high density lipoprotein
    Aminian, All
    Zelisko, Andrea
    Kirwan, John P.
    Brethauer, Stacy A.
    Schauer, Philip R.
    [J]. SURGERY FOR OBESITY AND RELATED DISEASES, 2015, 11 (01) : 238 - 247
  • [4] [Anonymous], 2014, COCHRANE DATABASE SY
  • [5] Metabolic/Bariatric Surgery Worldwide 2008
    Buchwald, Henry
    Oien, Danette M.
    [J]. OBESITY SURGERY, 2009, 19 (12) : 1605 - 1611
  • [6] The Clavien-Dindo Classification of Surgical Complications Five-Year Experience
    Clavien, Pierre A.
    Barkun, Jeffrey
    de Oliveira, Michelle L.
    Vauthey, Jean Nicolas
    Dindo, Daniel
    Schulick, Richard D.
    de Santibanes, Eduardo
    Pekolj, Juan
    Slankamenac, Ksenija
    Bassi, Claudio
    Graf, Rolf
    Vonlanthen, Rene
    Padbury, Robert
    Cameron, John L.
    Makuuchi, Masatoshi
    [J]. ANNALS OF SURGERY, 2009, 250 (02) : 187 - 196
  • [7] National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants
    Danaei, Goodarz
    Finucane, Mariel M.
    Lu, Yuan
    Singh, Gitanjali M.
    Cowan, Melanie J.
    Paciorek, Christopher J.
    Lin, John K.
    Farzadfar, Farshad
    Khang, Young-Ho
    Stevens, Gretchen A.
    Rao, Mayuree
    Ali, Mohammed K.
    Riley, Leanne M.
    Robinson, Carolyn A.
    Ezzati, Majid
    [J]. LANCET, 2011, 378 (9785) : 31 - 40
  • [8] GASTROINTESTINAL QUALITY-OF-LIFE INDEX - DEVELOPMENT, VALIDATION AND APPLICATION OF A NEW INSTRUMENT
    EYPASCH, E
    WILLIAMS, JI
    WOODDAUPHINEE, S
    URE, BM
    SCHMULLING, C
    NEUGEBAUER, E
    TROIDL, H
    [J]. BRITISH JOURNAL OF SURGERY, 1995, 82 (02) : 216 - 222
  • [9] Years of life lost due to obesity
    Fontaine, KR
    Redden, DT
    Wang, CX
    Westfall, AO
    Allison, DB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (02): : 187 - 193
  • [10] Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care
    Jones, R.
    Junghard, O.
    Dent, J.
    Vakil, N.
    Halling, K.
    Wernersson, B.
    Lind, T.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (10) : 1030 - 1038